Skip to main content

Termination of pregnancy for fetal neurological abnormalities

Child's Nervous System volume 19, pages 600–604 (2003)Cite this article

Abstract

Introduction

Prenatal screening for fetal abnormalities may identify conditions likely to result in perinatal death or in survival with a risk of handicap, for which termination of pregnancy is legal in many countries.

Discussion

When considering termination of pregnancy, it is crucial that prenatal diagnosis be as accurate as possible and that the prognosis of the condition diagnosed in utero is thoroughly understood by the parents. Our ability to predict postnatal outcome in borderline cases should not be overestimated. Parents should not precipitate their decision, and in some European countries, the absence of a gestational age limit at which a termination may be performed is viewed as a guarantee against hasty terminations. Maternal morbidity potentially associated with termination should be kept as low as possible. This includes maternal analgesia, and avoiding uterine trauma to preserve fertility and to prevent obstetrical complications in subsequent pregnancies. Bereavement should also be taken into account. Tests that could contribute to confirming the diagnosis or to establishing the aetiology of the abnormality, such as fetal karyotype or platelet count, should be implemented when appropriate, since post-termination genetic counselling relies on such data. Post-mortem examination is often crucial for genetic counselling and should include X-rays and gross examination of the fetus as well as brain and spine examination by a neuropathologist with expertise in the field of fetal medicine. Specific post-mortem procedures sometimes need to be planned before termination, for instance, in fetal akinesia sequence. First trimester surgical techniques and second or third trimester medical techniques of termination of pregnancy are reviewed.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Abortion Act 1967, as amended 1990. HMSO, London

  2. Bartley J, Baird DT (2002) A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. Br J Obstet Gynaecol 109:1290–1294

    Article  CAS  Google Scholar 

  3. Bosma JM, van der Wal G, Hosman-Benjaminse SL (1997) Late termination of pregnancy in North Holland. Br J Obstet Gynaecol 104:478–487

    CAS  PubMed  Google Scholar 

  4. Chapman SJ, Crispens M, Owen J, Savage K (1996) Complications of midtrimester pregnancy termination: the effect of prior cesarean delivery. Am J Obstet Gynecol 175:889–892

    CAS  PubMed  Google Scholar 

  5. Chervenak FA, Mccullough LB (1992) What is obstetric ethics. Clin Obstet Gynecol 35:709–719

    CAS  PubMed  Google Scholar 

  6. Child TJ, Thomas J, Rees M, MacKenzie IZ (2001) Morbidity of first trimester aspiration termination and the seniority of the surgeon. Hum Reprod 16:875–878

    Article  CAS  PubMed  Google Scholar 

  7. Dommergues M, Benachi A, Benifla JL, Des Noëttes R, Dumez Y (1999) The reasons for termination of pregnancy in the third trimester. Br J Obstet Gynaecol 106:297–303

    CAS  PubMed  Google Scholar 

  8. Dommergues M, Cahen F, Garel M, Mahieu-Caputo D, Dumez Y (2003) Feticide during second- and third-trimester termination of pregnancy: opinions of health care professionals. Fetal Diagn Ther 18:91–97

    Article  CAS  PubMed  Google Scholar 

  9. Frydman R, Fernandez H, Pons JC, Ulmann A (1988) Mifepristone (RU486) and therapeutic late pregnancy termination: a double-blind study of two different doses. Hum Reprod 3:803–806

    CAS  PubMed  Google Scholar 

  10. Garel M, Cahen F, Gaudebout P, Dommergues M, Goujard J, Dumez Y (2001) L'opinion des couples sur l'interruption médicale de grossesse. Gynecol Obstet Fertil 29:358–370

    Article  CAS  PubMed  Google Scholar 

  11. Geller G, Tambor ES, Papiernik E (1993) Attitudes toward abortion for fetal anomaly in the second vs. third trimester: a survey of Parisian obstetricians. Prenat Diagn 13:707–722

    CAS  PubMed  Google Scholar 

  12. Green JM (1995) Obstetricians' views on prenatal diagnosis and termination of pregnancy: 1980 compared with 1993. Br J Obstet Gynaecol 102:228–232

    CAS  PubMed  Google Scholar 

  13. Henriet L, Kaminski M (2001) Impact of induced abortions on subsequent pregnancy outcome: the 1995 French national perinatal survey. Br J Obstet Gynaecol 108:1036–1042

    Article  CAS  Google Scholar 

  14. Herabutya Y, Chanrachakul B, Punyavachira P (2001) Second trimester pregnancy termination: a comparison of 600 and 800 micrograms of intravaginal misoprostol. J Obstet Gynaecol Res 27:125–128

    CAS  PubMed  Google Scholar 

  15. Hill NC, MacKenzie IZ (1990) Early termination of pregnancy: medical induction with prostaglandins versus surgical aspiration under local anesthetic. Int J Gynaecol Obstet 32:269–274

    CAS  PubMed  Google Scholar 

  16. Hoffer MC, Charlier C, Giacalone PL, Zimbris L, Astruc M, Boulot P (1998) Evaluation de l'association RU 486-laminaires-misoprostol-peridurale anesthésie dans les interruptions médicales de grossesse au deuxième et au troisième trimestre de la grossesse. J Gynecol Obstet Biol Reprod (Paris) 27:83–86

    Google Scholar 

  17. Hunfeld JAM, Wladimiroff JW, Passchier J, Uniken Venema-Van Uden M, Frets PG, Verhage F (1993) Emotional reactions in women in late pregnancy (24 weeks or longer) following the ultrasound diagnosis of a severe or lethal fetal malformation. Prenat Diagn 13:603–612

    CAS  PubMed  Google Scholar 

  18. Jannet D, Aflak N, Abankwa A, Carbonne B, Marpeau L, Milliez J (1996) Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol. Eur J Obstet Gynecol Reprod Biol 70:159–163

    Article  CAS  PubMed  Google Scholar 

  19. Jannet D, Aflak N, Chemla JP, Marpeau L, Milliez J (1996) Mifepristone et misoprostol dans les avortements thérapeutiques. J Gynecol Obstet Biol Reprod (Paris) 25:277–282

    Google Scholar 

  20. Journal Officiel de la République Française, 17th of January 1975, Law n°75.17

  21. Journal Officiel de la République Française, 29th of July 1994, Law n°94. 647

  22. Journal Officiel de la République Française, Décret n°95–578 du 28–5-1997

  23. Jurgensen U, Christensen NJ (1989) Cervagem/Dilapan for preoperative cervical dilatation prior to vacuum aspiration for termination of first trimester pregnancy. A prospective randomized study. Contraception 40:741–749

    CAS  PubMed  Google Scholar 

  24. Kulier R, Fekih A, Hofmeyr GJ, Campana A (2001) Surgical methods for first trimester termination of pregnancy. Cochrane Database Syst Rev CD002900

  25. Lorenzen J, Holzgreve W (1995) Helping parents to grieve after second trimester termination of pregnancy for fetopathic reasons. Fetal Diagn Ther 10:147–156

    CAS  PubMed  Google Scholar 

  26. Mahieu-Caputo D, Dommergues M, Dumez Y (2002) Arrêt de vie in utero. In: Mirlesse V (ed) Interruption médicale de grossesse pour pathologie foetale. Flammarion Médecine Science, Paris, p 44

  27. Ngai SW, Yeung KC, Lao T, Ho PC (1995) Oral misoprostol versus vaginal gemeprost for cervical dilatation prior to vacuum aspiration in women in the sixth to twelfth week of gestation. Contraception 51:347–350

    Article  CAS  PubMed  Google Scholar 

  28. Ngai SW, Tang OS, Lao T, Ho PC, Ma HK (1995) Oral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancy. Hum Reprod 10:1220–1222

    CAS  PubMed  Google Scholar 

  29. Ngai SW, Yeung KC, Lao T, Ho PC (1996) Misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomised study. Br J Obstet Gynaecol 103:1120–1123

    CAS  PubMed  Google Scholar 

  30. Ngai SW, Tang OS, Ho PC (2000) Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Hum Reprod 15:2205–2208

    Article  CAS  PubMed  Google Scholar 

  31. Perrotte F, Mirlesse V, De Vigan C, Kieffer F, Meunier E, Daffos F (2000) Interruption médicale de grossesse pour anomalie foetale: point de vue des patientes. J Gynecol Obstet Biol Reprod (Paris) 2:185–191

    Google Scholar 

  32. Pridmore BR, Chambers DG (1999) Uterine perforation during surgical abortion: a review of diagnosis, management and prevention. Aust NZ J Obstet Gynaecol 39:349–353

    CAS  Google Scholar 

  33. Rodeck CH, Bewley S (1994) Late abortion for fetal abnormality. In: Bewley S, Ward RHT (eds) Late abortion for fetal abnormality. RCOG Press, London, pp 262–267

  34. Thomas AG, Alvarez M, Friedman F Jr, Brodman ML, Kim J, Lockwood C (1994) The effect of placenta previa on blood loss in second-trimester pregnancy termination. Obstet Gynecol 84:58–60

    CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Maternité, Hôpital Necker Enfants Malades, AP-HP and Université Paris V, 149 rue de Sèvres, 75743, Paris Cedex 15, France

    Marc Dommergues

Authors
  1. Marc Dommergues
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Dommergues.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dommergues, M. Termination of pregnancy for fetal neurological abnormalities. Childs Nerv Syst 19, 600–604 (2003). https://doi.org/10.1007/s00381-003-0780-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-003-0780-7

Keywords

  • Abortion
  • Termination of pregnancy
  • Mifepristone
  • Misoprostol
  • Dilapan
  • Feticide